MCRB
Seres Therapeutics Inc
4.00$
-1.2%
vs. previous close
Closing price · As of: Sep 22, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +84.8% | +25.7% | -30.5% | -36.4% | +9.9% | +158.9% | +3.5% | -1.7% | +2.8% | -61.0% | -1.2% | |
| – | +81.7% | -4.5% | -21.8% | -40.2% | +8.1% | +168.3% | +13.0% | -35.9% | -9.9% | -78.0% | +27.7% | |
| – | -35.3% | -26.2% | -33.8% | +137.8% | -24.1% | +78.2% | +55.1% | -9.4% | -21.5% | -75.9% | +48.6% | |
| – | +79.6% | -5.8% | -22.4% | -42.8% | +10.5% | +167.5% | +14.6% | -37.6% | -29.4% | -75.9% | +48.6% | |
| – | – | – | – | – | – | +425.9% | -100.0% | – | – | -45.2% | -92.4% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +513.2% | +366.1% | -8.8% | -20.2% | -25.9% | -28.7% | +160.1% | -36.4% | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -92.0% | +1,116.9% | -8.0% | +30.8% | +7.3% | -7.0% | +32.8% | +51.3% | +19.4% | -68.8% | -25.4% | |
| – | +114.0% | +178.9% | +3.8% | +32.9% | +9.4% | +0.9% | +77.2% | +4.1% | +15.3% | -58.2% | -53.1% | |
| – | – | – | +22.9% | +30.9% | -63.1% | +25.0% | +18.7% | -38.6% | +37.7% | +55.3% | +19.8% | |
| – | +149.2% | +40.6% | -7.3% | -8.8% | -24.3% | -17.3% | +241.8% | +27.0% | -79.1% | +12.0% | -58.8% | |
| – | -100.0% | – | – | – | – | 0.0% | +0.0% | +105.3% | +100.7% | – | – | |
| – | – | -35.4% | -54.2% | -179.2% | – | – | -24.7% | -91.8% | -516.0% | – | +220.8% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -39.6% | +69.3% | +1.5% | +0.7% | +39.0% | +40.8% | +14.9% | +17.9% | +18.4% | +21.4% | +14.2% |
Data as of: September 22, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.